The painkillers market will reach $68.0 billion in 2013, says Visiongain.

LONDON - Aug. 2, 2013 - PRLog -- Visiongain predicts that the world market for drugs to relieve pain will reach $68.0 billion for 2013. That revenue forecast appears in World Pain Relieving Drug Market 2013-2023, published in July 2013. Visiongain is a business information provider based in London UK.

The study forecasts that the overall market for pain relieving drugs will grow steadily from 2013 to 2023. The world pain-treating drug market is a high-revenue industry with a high public and healthcare profile. Market growth will be stimulated by rises in disease prevalence, ageing populations and prevalence of cancer, arthritis and diabetes.

Growth of the pain treatment market will continue to be stimulated by new drugs and reformulations of existing products from 2013 onwards. The launch of new treatments, including more-efficacious drugs, improved drug delivery and new dosing schedules, will increase revenues. Visiongain believes that increasing public awareness and the development of submarkets such as neuropathic and cancer pain treatment will be crucial to expansion of the industry and the market.

Rodrigo Gutierrez Gamboa, a pharmaceutical industry analyst in visiongain said: “The pain relief market continues to be a dynamic, high-revenue market that can be profitable, even if it is challenging for participating companies. The world population is experiencing an increase in disease prevalence, as a result of an ageing world population and high, rising incidence of cancer, arthritis and diabetes. This will result in the pain drug market being driven towards revenue growth from 2013. Market expansion will continue to be dependent upon reformulations of existing drugs and launch of novel pain treatments, providing more-efficacious drugs, improved drug delivery, new dosing schedules and better-served patient populations.”

Visiongain’s report shows revenue forecasts to 2023 at overall world market, submarket, product and national level. The study includes OTC (over-the-counter) and Rx (prescription) pain relieving medicines. It forecasts these world-level submarkets:

·         Narcotics

·         Non-narcotics

·         Neuropathic pain relievers

·         Treatments for migraines

·         Treatments for arthritis.

The investigation predicts revenues of 29 leading drugs in the painkillers market, including Oxycontin ER, Panadol, Lyrica and Zomig. Research, data and analyses cover activities of Pfizer, GSK, Johnson and Johnson, Bristol-Myers Squibb and other pharmaceutical companies.

That report discusses R&D and commercial news, shows research interviews and forecasts revenues in leading national markets. The work analyses the US, Japan, five leading EU countries (the EU5), India, China, Brazil, Russia and Turkey.

World Pain Relieving Drug Market 2013-2023 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Biomarkers: Technological and Commercial Outlook 2013 please visit http://www.visiongain.com/Report/1088/World-Pain-Relieving-Drug-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.